Prostate cancer (PCa) is the most common cancer among men in western countries. While active surveillance is increasingly utilized, the majority of patients are currently treated with radical prostatectomy.
In order to avoid over-treatment, there is an indisputable need for reliable biomarkers to identify the potentially aggressive and lethal cases. Nuclear intermediate filament proteins called lamins play a role in chromatin organization, gene expression and cell stiffness. The expression of lamin A is associated with poor outcome in colorectal cancer but to date the prognostic value of the lamins has not been tested in other solid tumors.
We studied the expression of different lamins with immunohistochemistry in a tissue microarray material of 501 PCa patients undergoing radical prostatectomy and lymph node dissection. Patients were divided into two staining categories (low and high expression). The correlation of lamin expression with clinicopathological variables was tested and the association of lamin status with biochemical recurrence (BCR) and disease specific survival (DSS) was further analyzed.
Low expression of lamin A associated with lymph node positivity (p
These results suggest differential roles for lamins in PCa progression. Reduced amounts of lamin A/C and B2 increase risk for lymph node metastasis and disease specific death possibly through increased nuclear deformability while high expression of lamin B1 predicts disease recurrence.
PloS one. 2015 Oct 15*** epublish ***
Irena Saarinen, Tuomas Mirtti, Heikki Seikkula, Peter J Boström, Pekka Taimen
Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland; MediCity, Research Laboratory, University of Turku, Turku, Finland. , Department of Pathology, Helsinki University Hospital and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland. , Department of Urology, Turku University Hospital, Turku, Finland. , Department of Urology, Turku University Hospital, Turku, Finland. , Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland; MediCity, Research Laboratory, University of Turku, Turku, Finland.